-
1.
公开(公告)号:JP2013049681A
公开(公告)日:2013-03-14
申请号:JP2012225875
申请日:2012-10-11
Applicant: Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
Inventor: WAGNER ROLF , TUFANO MICHAEL D , STEWART KENT D , ROCKWAY TODD W , RANDOLPH JOHN T , PRATT JOHN K , MOTTER CHRISTOPHER E , MARING CLARENCE J , LONGENECKER KENTON L , LIU YAYA , LIU DACHUN , KRUEGER ALLAN C , KATI WARREN M , HUTCHINSON DOUGLAS K , HUANG PEGGY P , FLENTGE CHARLES A , DONNER PAMELA L , DEGOEY DAVID A , BETEBENNER DAVID A , BARNES DAVID M , CHEN SHUANG , FRANCZYK II THADDEUS S , GAO YI , HAIGHT ANTHONY R , HENGEVELD JOHN E , HENRY RODGER F , KOTECKI BRIAN J , LOU XIAOCHUN , SARRIS KATHY , ZHANG GEOFF G Z
IPC: C07D239/22 , A61K31/513 , A61K31/5377 , A61P1/16 , A61P31/14 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
CPC classification number: A61K31/513 , A61K31/5377 , C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
Abstract: PROBLEM TO BE SOLVED: To provide compounds useful to treat hepatitis C (HCV) infections.SOLUTION: In the compounds, the uracil or thymine derivative are linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t-butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1(2H)-yl)2-methoxy-styryl-phenyl)methanesulfonamide.
Abstract translation: 待解决的问题:提供可用于治疗丙型肝炎(HCV)感染的化合物。 解决方案:在化合物中,尿嘧啶或胸腺嘧啶衍生物通过亚苯连接成稠合的2-环环系(R6),或者通过另外的两个原子连接基(L)连接到5-6元单环(R6 )。 应用进一步公开了两种特定化合物的多晶型物和假多晶型物:N-(6(3-叔丁基-5-(2,4-二氧代-3,4-二氢嘧啶-1(2H) - 基)2-甲氧基 - 苯基) 萘-2-基)甲磺酰胺和(E)-N-(4(3-叔丁基-5-(2,4-二氧代-3)4-二氢嘧啶-1(2H) - 基)2-甲氧基苯乙烯基 苯基)甲磺酰胺。 版权所有(C)2013,JPO&INPIT
-
公开(公告)号:JP2013056886A
公开(公告)日:2013-03-28
申请号:JP2012221886
申请日:2012-10-04
Applicant: Abbott Lab , アボット・ラボラトリーズAbbott Laboratories
Inventor: FLENTGE CHARLES A , HUTCHINSON DOUGLAS K , BETEBENNER DAVID A , DEGOEY DAVID A , DONNER PAMELA L , KATI WARREN M , KRUEGER ALLAN C , LIU DACHUN , LIU YAYA , LONGENECKER KENTON L , MARING CLARENCE J , MOTTER CHRISTOPHER E , PRATT JOHN K , RANDOLPH JOHN T , ROCKWAY TODD W , STEWART KENT D , WAGNER ROLF , BARNES DAVID M , CHEN SHUANG , FRANCZYK II THADDEUS S , GAO YI , HAIGHT ANTHONY R , HENGEVELD JOHN E , KOTECKI BRIAN J , LOU XIAOCHUN , ZHANG GEOFF G Z
IPC: C07D239/22 , A61K31/506 , A61K31/513 , A61K45/00 , A61P31/14 , A61P43/00 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
CPC classification number: C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
Abstract: PROBLEM TO BE SOLVED: To provide anti-infective agents and the like, used either in combination with or in lieu of an interferon agent and/or ribavirin.SOLUTION: This invention relates to: (a) compounds and salts thereof that inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 要解决的问题:提供与干扰素和/或利巴韦林组合或代替干扰素剂和/或利巴韦林使用的抗感染剂等。 本发明涉及:(a)抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。 版权所有(C)2013,JPO&INPIT
-
公开(公告)号:WO2012083061A3
公开(公告)日:2012-08-02
申请号:PCT/US2011065247
申请日:2011-12-15
Applicant: ABBOTT LAB , KRUEGER ALLAN C , KATI WARREN M , MARING CLARENCE J , WAGNER ROLF , HUTCHINS CHARLES W
Inventor: KRUEGER ALLAN C , KATI WARREN M , MARING CLARENCE J , WAGNER ROLF , HUTCHINS CHARLES W
IPC: C07D403/14 , A61K31/4178 , A61P31/14 , C07D403/10 , C07D403/12
CPC classification number: C07D403/14 , C07D401/14 , C07D413/14 , C07D417/14
Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
-
公开(公告)号:WO2012083048A3
公开(公告)日:2012-08-02
申请号:PCT/US2011065215
申请日:2011-12-15
Applicant: ABBOTT LAB , KRUEGER ALLAN C , KATI WARREN M , MARING CLARENCE J , WAGNER ROLF , HUTCHINS CHARLES W
Inventor: KRUEGER ALLAN C , KATI WARREN M , MARING CLARENCE J , WAGNER ROLF , HUTCHINS CHARLES W
IPC: C07D401/14 , A61K31/4439 , A61P31/00 , C07D401/12
CPC classification number: C07K5/06052 , A61K31/4439 , C07D401/12 , C07D401/14 , C07D403/14
Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
Abstract translation: 本发明涉及抗HCV化合物,包含其的组合物以及使用该化合物治疗HCV感染的方法。
-
5.PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF NEURAMINIDASES 审中-公开
Title translation: 吡咯啉衍生物,其制备及其作为神经酰胺酶抑制剂的用途公开(公告)号:WO0128996A3
公开(公告)日:2001-11-29
申请号:PCT/US0027910
申请日:2000-10-10
Applicant: ABBOTT LAB , MARING CLARENCE J , GIRANDA VINCENT L , KEMPF DALE J , STOLL VINCENT S , SUN MINGHUA , ZHAO CHEN , GU YU GUI , HANESSIAN STEPHEN , WANG GARY T , KRUEGER ALLAN C , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GRAMPOVNIK DAVID J , KATI WARREN M , KENNEDY APRIL L , KLEIN LARRY L , LIN ZHEN , MADIGAN DAROLD L
Inventor: MARING CLARENCE J , GIRANDA VINCENT L , KEMPF DALE J , STOLL VINCENT S , SUN MINGHUA , ZHAO CHEN , GU YU GUI , HANESSIAN STEPHEN , WANG GARY T , KRUEGER ALLAN C , CHEN HUI-JU , CHEN YUANWEI , DEGOEY DAVID A , FLOSI WILLIAM J , GRAMPOVNIK DAVID J , KATI WARREN M , KENNEDY APRIL L , KLEIN LARRY L , LIN ZHEN , MADIGAN DAROLD L
IPC: C07D401/12 , A61K31/357 , A61K31/40 , A61K31/401 , A61K31/4025 , A61K31/405 , A61K31/415 , A61K31/4155 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/425 , A61K31/427 , A61K31/4439 , A61K31/5377 , A61K31/66 , A61K31/662 , A61P31/00 , A61P31/12 , A61P31/16 , A61P43/00 , C07D20060101 , C07D207/00 , C07D207/12 , C07D207/16 , C07D207/26 , C07D207/32 , C07D207/327 , C07D207/38 , C07D207/46 , C07D303/16 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D407/06 , C07D407/12 , C07D409/06 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D521/00 , C07F9/40 , C07F9/572
CPC classification number: C07D207/16 , C07D207/26 , C07D207/327 , C07D207/38 , C07D207/46 , C07D231/12 , C07D233/56 , C07D249/08 , C07D303/16 , C07D403/04 , C07D405/04 , C07D405/06 , C07D409/06 , C07D413/04 , C07D417/04 , C07D417/06
Abstract: Enantiomerically enriched compounds having the absolute stereochemistry of the formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.
-
公开(公告)号:WO2012083053A3
公开(公告)日:2012-08-02
申请号:PCT/US2011065224
申请日:2011-12-15
Applicant: ABBOTT LAB , KRUEGER ALLAN C , KATI WARREN M , MARING CLARENCE J , WAGNER ROLF , HUTCHINS CHARLES W
Inventor: KRUEGER ALLAN C , KATI WARREN M , MARING CLARENCE J , WAGNER ROLF , HUTCHINS CHARLES W
IPC: C07D403/14 , A61K31/4178 , A61P31/00 , C07D403/10 , C07D409/14
CPC classification number: C07D403/14 , C07D409/14
Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
-
公开(公告)号:WO2010075376A2
公开(公告)日:2010-07-01
申请号:PCT/US2009069177
申请日:2009-12-22
Applicant: ABBOTT LAB , DEGOEY DAVID A , DONNER PAMELA L , KATI WARREN M , HUTCHINS CHARLES W , MATULENKO MARK A , JINKERSON TAMMIE K , KEDDY RYAN G
Inventor: DEGOEY DAVID A , DONNER PAMELA L , KATI WARREN M , HUTCHINS CHARLES W , MATULENKO MARK A , JINKERSON TAMMIE K , KEDDY RYAN G
IPC: C07D471/04 , A61K31/519 , A61P31/14
CPC classification number: C07D471/04
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号:WO0128979A3
公开(公告)日:2001-12-27
申请号:PCT/US0027938
申请日:2000-10-10
Applicant: ABBOTT LAB
Inventor: MARING CLARENCE J , GIRANDA VINCENT L , KEMPF DALE J , STOLL VINCENT S , SUN MINGHUA , ZHAO CHEN , GU YU GUI , WANG GARY T , KRUEGER ALLAN C , CHEN YUANWEI , DEGOEY DAVID A , GRAMPOVNIK DAVID J , KATI WARREN M , KENNEDY APRIL L , LIN ZHEN , MADIGAN DONALD L , MUCHMORE STEVEN W , SHAM HING L , STEWART KENT D , WANG SHELDON , YEUNG MING C
IPC: A61K31/195 , C07C233/48 , C07C237/24 , C07C271/22 , C07C271/24 , C07C279/16 , C07D233/54 , C07D263/32 , C07D307/24 , C07D317/30 , C07D405/04 , A61K31/325 , A61K31/34 , A61K31/415 , A61K31/42 , A61P31/00
CPC classification number: C07D233/64 , C07B2200/07 , C07B2200/09 , C07C233/48 , C07C237/24 , C07C271/22 , C07C271/24 , C07C279/16 , C07C2601/08 , C07C2601/10 , C07D263/32 , C07D307/24 , C07D317/30 , C07D405/04
Abstract: Disclosed are compounds of formula (I), (II) or (III) which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.
Abstract translation: 公开了可用于抑制致病微生物,特别是流感神经氨酸酶的神经氨酸酶的式(I),(II)或(III)的化合物。 还公开了用于预防和治疗由具有神经氨酸酶的微生物引起的疾病的组合物和方法,用于制备这些方法中使用的化合物和合成中间体的方法。
-
公开(公告)号:WO2010111436A3
公开(公告)日:2011-04-07
申请号:PCT/US2010028560
申请日:2010-03-25
Applicant: ABBOTT LAB , BETEBENNER DAVID A , PRATT JOHN K , DEGOEY DAVID A , DONNER PAMELA L , FLENTGE CHARLES A , HUTCHINSON DOUGLAS K , KATI WARREN M , KRUEGER ALLAN C , LONGENECKER KENTON L , MARING CLARENCE J , RANDOLPH JOHN T , ROCKWAY TODD W , TUFANO MICHAEL D , WAGNER ROLF
Inventor: BETEBENNER DAVID A , PRATT JOHN K , DEGOEY DAVID A , DONNER PAMELA L , FLENTGE CHARLES A , HUTCHINSON DOUGLAS K , KATI WARREN M , KRUEGER ALLAN C , LONGENECKER KENTON L , MARING CLARENCE J , RANDOLPH JOHN T , ROCKWAY TODD W , TUFANO MICHAEL D , WAGNER ROLF
IPC: C07C15/58 , A61K31/4412 , A61K31/513 , A61P31/14 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/74 , C07D239/10 , C07D239/54 , C07D263/22 , C07D275/02 , C07D403/10 , C07D405/10 , C07D409/10
CPC classification number: C07D409/10 , A61K31/18 , A61K31/27 , A61K31/402 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/4418 , A61K31/503 , A61K31/513 , A61K45/06 , C07C311/08 , C07D207/27 , C07D213/64 , C07D233/32 , C07D233/72 , C07D239/10 , C07D239/54 , C07D263/22 , C07D263/24 , C07D275/02 , C07D403/10 , C07D405/10 , Y02P20/55
Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
Abstract translation: 本发明涉及:(a)特别是抑制HCV的化合物及其盐; (b)可用于制备这些化合物和盐的中间体; (c)包含这些化合物和盐的组合物; (d)制备这种中间体,化合物,盐和组合物的方法; (e)使用这些化合物,盐和组合物的方法; 和(f)包含这些化合物,盐和组合物的试剂盒。
-
公开(公告)号:WO2010144646A2
公开(公告)日:2010-12-16
申请号:PCT/US2010038077
申请日:2010-06-10
Applicant: ABBOTT LAB , DEGOEY DAVID A , KATI WARREN M , HUTCHINS CHARLES W , DONNER PAMELA L , KRUEGER ALLAN C , RANDOLPH JOHN T , MOTTER CHRISTOPHER E , NELSON LISSA T , PATEL SACHIN V , MATULENKO MARK A , KEDDY RYAN G , JINKERSON TAMMIE K , SOLTWEDEL TODD N , HUTCHINSON DOUGLAS K , FLENTGE CHARLES A , WAGNER ROLF , MARING CLARENCE J , TUFANO MICHAEL D , BETEBENNER DAVID A , ROCKWAY TODD W , LIU DACHUN , PRATT JOHN K , LAVIN MICHAEL J , SARRIS KATHY , WOLLER KEVIN R , WAGAW SEBLE H , CALIFANO JEAN C , LI WENKE
Inventor: DEGOEY DAVID A , KATI WARREN M , HUTCHINS CHARLES W , DONNER PAMELA L , KRUEGER ALLAN C , RANDOLPH JOHN T , MOTTER CHRISTOPHER E , NELSON LISSA T , PATEL SACHIN V , MATULENKO MARK A , KEDDY RYAN G , JINKERSON TAMMIE K , SOLTWEDEL TODD N , HUTCHINSON DOUGLAS K , FLENTGE CHARLES A , WAGNER ROLF , MARING CLARENCE J , TUFANO MICHAEL D , BETEBENNER DAVID A , ROCKWAY TODD W , LIU DACHUN , PRATT JOHN K , LAVIN MICHAEL J , SARRIS KATHY , WOLLER KEVIN R , WAGAW SEBLE H , CALIFANO JEAN C , LI WENKE
IPC: C07D403/14
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 描述了有效抑制丙型肝炎病毒(“HCV”)复制的化合物。 本发明还涉及制备这种化合物的方法,包含这些化合物的组合物,以及使用这些化合物治疗HCV感染的方法。
-
-
-
-
-
-
-
-
-